<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34725">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654522</url>
  </required_header>
  <id_info>
    <org_study_id>HH101</org_study_id>
    <nct_id>NCT02654522</nct_id>
  </id_info>
  <brief_title>The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers</brief_title>
  <official_title>The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steve Yoelin M.D. Medical Associates, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steve Yoelin M.D. Medical Associates, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase
      (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA)
      dermal fillers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous Augmentation Grading Scale (Vartanian et al, 2005)</measure>
    <time_frame>2-6 hours post initial injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photography (Volar Aspect) at Site of Injection</measure>
    <time_frame>1-6 hours post initial injection day 1, day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-dimensional (3-D) ultrasound imaging</measure>
    <time_frame>1-6 hours post initial injection day 1, day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Dermal Filler</condition>
  <arm_group>
    <arm_group_label>Filler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylenex</intervention_name>
    <description>1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).</description>
    <arm_group_label>Filler</arm_group_label>
    <other_name>Hyaluronidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older

          -  Able to speak/write in the English language

          -  Negative Pregnancy Test on Day 1

          -  Proposed injection site must be free of any active inflammation

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  History of keloid formation

          -  History of allergic reaction to hyaluronic acid dermal fillers, hyaluronidase, or any
             ingredients of the aforementioned products

          -  Active, uncontrolled inflammatory condition of any type

          -  History of allergic reaction to lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven G Yoelin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steve Yoelin M.D. Medical Associates, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven G Yoelin, M.D.</last_name>
    <phone>(714) 973-0330</phone>
    <email>syoelinmd@gmail.com</email>
  </overall_contact>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 12, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steve Yoelin M.D. Medical Associates, Inc.</investigator_affiliation>
    <investigator_full_name>Steven Yoelin</investigator_full_name>
    <investigator_title>Steve Yoelin M.D.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
